Q-omics provides the consensus-scored TMEM167B-DT profile across patient tissues and cancer cell-line models. TMEM167B-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TMEM167B-DT is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TMEM167B-DT RNA expression shows 16,631 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KICH, and UVM as cancer lineages where TMEM167B-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM167B-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM167B-DT survival associations across molecular data types. TMEM167B-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM167B-DT RNA expression–survival associations across cancer types. High TMEM167B-DT expression shows unfavorable associations in BLCA and UCEC, but favorable associations in PAAD, MESO, SARC and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TMEM167B-DT RNA expression.
This table summarizes TMEM167B-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM167B-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM167B-DT shows lower tumor expression in KICH, THCA, COAD, KIRC and BLCA and higher tumor expression in LIHC. The KICH box plot shows higher TMEM167B-DT RNA expression in normal versus tumor tissue (log2 FC = −1.591, t-test p < 0.001).
This table shows molecular features associated with TMEM167B-DT in patient tissues and cancer cell lines. In patient samples, TMEM167B-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
